Clinical, nutritional and spirometric evaluation of patients with cystic fibrosis after the implementation of multidisciplinary treatment

Torres, Lídia; Hernandez, Jenny Libeth Jurado; De Almeida, Giseli Barbiero; Gomide, Liana Barbaresco; Ambrósio, Valéria; Fernandes, Maria Inez Machado
November 2010
Jornal Brasileiro de Pneumologia;nov2010, Vol. 36 Issue 6, p731
Academic Journal
Objective: Cystic fibrosis (CF) is a chronic multisystemic hereditary disease for which a multidisciplinary approach must be taken. The objective of this study was to show the evolution of a group of patients with CF after the implementation of multidisciplinary treatment. Methods: A retrospective study involving 19 patients (6-29 years of age) under clinical follow-up treatment at the University of São Paulo at Ribeirão Preto School of Medicine Hospital das Clínicas, located in the city of Ribeirão Preto, Brazil. The patients were divided into two groups: 6-12 (6-12 years of age) and 13+ (> 12 years of age). We collected data regarding body mass index (BMI), Z score, Shwachman score (SS), number of exacerbations/year, chronic colonization by Pseudomonas aeruginosa, and spirometric measurements (FVC, FEV1, FEV1%, and FEF25-75%). Data were collected at two different time points (before and after the implementation of the multidisciplinary treatment) and were analyzed with the Wilcoxon signed rank test. Results: The median age at the onset of symptoms was 10 months. In the 6-12 group, only BMI and FVC increased significantly. Although the other spirometric values increased, the differences were not significant. In the 13+ group, there were no significant differences between the two time points. There was a borderline significant decrease in SS and less than significant decreases in the spirometric measurements. However, the number of patients with alterations in volumes and flows decreased in both groups. Conclusions: Although our patient sample was small, the lack of changes in the spirometric parameters might reflect clinical and functional stability. In all of the patients evaluated, clinical, functional, and nutritional parameters remained stable throughout the study period. The implementation of a multidisciplinary approach might have contributed to this result.


Related Articles

  • Can Curcumin Cure Cystic Fibrosis? Zeitlin, Pamela // New England Journal of Medicine;8/5/2004, Vol. 351 Issue 6, p606 

    Offers a look at research into treatments for cystic fibrosis as of August 2004. Statement that cystic fibrosis is a progressive and fatal inherited disorder caused by a mutant cystic fibrosis transmembrane conductance regulator; Reference to a medical study on curcumin, a nutraceutical agent,...

  • Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis. Hatziagorou, E.; Avramidou, V.; Kirvassilis, F.; Tsanakas, J. // Hippokratia;2015, Vol. 19 Issue 1, p47 

    Background: Progressive lung disease is the main cause of clinical deterioration and mortality in cystic fibrosis (CF) patients. Being able to assess the effectiveness of interventions is very significant. Objectives: To assess the response to intravenous (IV) treatment among CF patients, using...

  • Cystic fibrosis care guidelines launched.  // Australian Nursing Journal;Mar2000, Vol. 7 Issue 8, p12 

    Announces the launching of guidelines for the treatment of cystic fibrosis by the Clinical Standards Advisory Group of the Cystic Fibrosis Care Alliance (CFCA) in Victoria. Background information on CFCA; Benefits of the guidelines.

  • Cystic fibrosis. Knott, Laurence // GP: General Practitioner;5/2/2008, p26 

    The article offers information on the symptoms and treatment of cystic fibrosis (CF) in patients in Great Britain. It is an autosomal recessive disorder caused by a mutation at the CF transmembrane conductance regulator gene that affects various cellular activities. It can be present at any age...

  • Atypical presentation of cystic fibrosis - obese adolescent with hypertension and pseudo-Bartter's syndrome. Sovtić, Aleksandar; Minić, Predrag; Bogdanović, Radovan; Stajić, Nataša; Rodić, Milan; Marković-Sovtić, Gordana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Apr2012, Vol. 69 Issue 4, p367 

    Introduction. Infants with cystic fibrosis may fail to thrive despite recommended caloric intake because of electrolyte disurbances caused by salt depletion resulting in hypochloremic metabolic alkalosis or pseudo-Bartter's syndrome. In most patients reported symptoms began in infancy, but it...

  • Inspire Drug for CF Fares Well in Phase III.  // Bioworld Week;6/16/2008, Vol. 16 Issue 24, p2 

    The article reports on the effectivity of denufosol, a drug for cystic fibrosis (CF) Inspire Pharmaceuticals Inc., a company based in Durham, North Carolina. In the Phase III trial of 352 patients, denufosol was improved the ability of patients to exhale compared to placebo in a six-month study....

  • Cystic fibrosis combo treatment meets phase 3 endpoints.  // Nature Biotechnology;Aug2014, Vol. 32 Issue 8, p709 

    The article reports on phase 3 clinical trials of Vertex Pharmaceuticals' Kalydeco plus Lumacaftor combination treatment for cystic fibrosis (CF) and mentions that the drug improved the lung function of the patients during the trials as of August 2014.

  • Novel agents in cystic fibrosis. Storey, Shane; Wald, Graeme // Nature Reviews Drug Discovery;Jul2008, Vol. 7 Issue 7, p555 

    The article provides information on several therapeutic agents that improve the treatment of cystic fibrosis. It states that Pulmozyme drug from Genentech Inc. is a recombinant human DNase, which reduces mucus viscosity in the lungs. Moreover, it notes that the hyperosmolar agent Bronchitol is...

  • The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis. Suri, Ranjan // BioDrugs;2005, Vol. 19 Issue 3, p135 

    In patients with cystic fibrosis (CF), the poor clearance of airway secretions promotes recurrent cycles of pulmonary infection and inflammation. In recent years, novel drugs have been developed to alter the properties of the secretions in an attempt to aid chest physiotherapy in improving...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics